Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 25Carcinoma, Renal Cell 22Lung Neoplasms 11Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Colorectal Neoplasms 9Prostatic Neoplasms 8Hodgkin Disease 8Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Adenocarcinoma Of Esophagus 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Nasopharyngeal Carcinoma 4Multiple Myeloma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Carcinoma, Basal Cell 4Brain Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Sarcoma, Kaposi 3Recurrence 3

Interventions

varlilumab 1Nivolumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphomatoid Granulomatosis × Nivolumab × 30 days × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡